cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Travere Therapeutics Inc
7 own
1 watching
Current Price
$9.87
$0.1
(1.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
595.49M
52-Week High
52-Week High
17.56990
52-Week Low
52-Week Low
5.12000
Average Volume
Average Volume
0.55M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
59.2089
iconMarket Capitalization595.49M
icon52-Week High17.56990
icon52-Week Low5.12000
iconAverage Volume0.55M
iconDividend Yield--
iconP/E Ratio59.2089
What does the Travere Therapeutics Inc do?
Travere Therapeutics Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Read More
How much money does Travere Therapeutics Inc make?
News & Events about Travere Therapeutics Inc.
PR Newswire
1 year ago
TVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities Laws TVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities Laws PR Newswire NEW YORK, July 3, 2023 NEW YORK...
PR Newswire
1 year ago
TVTX FRAUD ALERT: Jakubowitz Law is Investigating Travere Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws TVTX FRAUD ALERT: Jakubowitz Law is Investigating...
PR Newswire
1 year ago
TVTX FRAUD ALERT: Jakubowitz Law is Investigating Travere Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws TVTX FRAUD ALERT: Jakubowitz Law is Investigating Travere Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws PR Newswire...
PR Newswire
1 year ago
TVTX INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Travere Therapeutics, Inc. TVTX INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities...
Ticker Report
1 year ago
Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX Get Rating) have earned an average recommendation of Moderate Buy from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and ...
Frequently Asked Questions
Frequently Asked Questions
What is Travere Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Travere Therapeutics Inc shares?
plus_minus_icon
How can I buy Travere Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Travere Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Travere Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Travere Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Travere Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Travere Therapeutics Inc?
plus_minus_icon
What percentage is Travere Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Travere Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.87
$0.1
(1.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$11.74
$0.46 (4.08 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$10.06
$-0.04 (-0.40 %)
Calliditas Therapeutics AB
Calliditas Therapeutics AB
$38.04
$-0.11 (-0.29 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$5.21
$0.01 (0.29 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$11.74
$0.46 (4.08 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$10.06
$-0.04 (-0.40 %)
Calliditas Therapeutics AB
Calliditas Therapeutics AB
$38.04
$-0.11 (-0.29 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$5.21
$0.01 (0.29 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00